LB Pharmaceuticals Inc
NASDAQ · us_market
No AI insight generated yet for this ticker.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 504.4K | $12.44M | 0.00% | Added+101.7% | 2026-03-31 |
| FidelityFMR | fundamental | 222.5K | $5.49M | 0.00% | Unchanged | 2026-03-31 |
| Wellington | fundamental | 52.6K | $1.30M | 0.00% | New | 2026-03-31 |
| TwoSigma | quant | 12.7K | $313.68K | 0.00% | Unchanged | 2026-03-31 |
| TRowePrice | fundamental | 13.2K | $327 | 0.00% | Added+19.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.81 | — | — |
| 2026-03-26 | -0.32 | -0.45 | -42.10% |
| 2025-11-06 | -0.28 | -0.61 | -117.86% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LBRX | -11.01% | +16.98% | +25.65% | — |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -13.98% | +21.62% | +29.09% | — |